NCT00187655|CompletedPhase 1ResultsDMC
Effect of, OAT3, on the Renal Secretion of Cefotaxime
Effect of Genetic Variation in the Transporter, OAT3, on the Renal Secretion of Cefotaxime
Loading search results
Sponsor study identifier
interventional
24
0 countries
N/A
Study Start
January 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2011
Actual (reported)Study Completion
December 2013
Actual (reported)In the proposed study, we plan to use a genotype to phenotype strategy to study the role of the organic anion transporter, OAT3, in drug response. More specifically we will examine the contribution of OAT3 to the renal clearance of anionic drugs such as cefotaxime by studying individuals with a non-functional (or poorly-functional) variant of OAT3.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2013
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2004
Date type not reportedThis date has not been verified as actual or estimated.
September 13, 2005
Actual (reported)September 16, 2005
Actual (reported)December 2011
Actual (reported)December 2013
Actual (reported)May 12, 2014
Actual (reported)Effect of OAT3 on Renal Secretion of Cefotaxime IV Based on Genotype
Participants were stratified by their OCT3 genotype, heterozygous vs homozygous. The renal clearance of cefotaxime was measured by urine content of cefotaxime metabolites in participants after the single IV push administration of 2 grams of cefotaxime.
post dose up to 24 hours
Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Erdman AR, Mangravite LM, Urban TJ, Lagpacan LL, Castro RA, de la Cruz M, Chan W, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Carlson EJ, Ferrin TE, Brett CM, Burchard EG, Giacomini KM. The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol Renal Physiol. 2006 Apr;290(4):F905-12. doi: 10.1152/ajprenal.00272.2005. Epub 2005 Nov 15.
Kathleen Giacomini, PhD
University of California, San Francisco
24 participants (actual enrollment reported by the registry).
First Submitted
September 13, 2005
First Posted
September 16, 2005
Study Start
January 2004
Date type not reportedThis date has not been verified as actual or estimated.
COACH-Cog Intervention Adaptation Focus Groups
Contact the study team to confirm eligibility.
Primary Completion
December 2011
Actual (reported)Study Completion
December 2013
Actual (reported)Last Updated
October 29, 2014
Results First Posted
May 12, 2014
Record last verified: 2014-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: